From the standpoint that the presence of the ER maintains cell responsiveness to endocrine therapy, such as with the selective ER modulator (SERM), tamoxifen, ER+ breast cancer itself represents a more treatable condition than the ER− phenotype. The gene discussed is ESR1; the disease is breast carcinoma.